Sheila Borboli-Gerogiannis, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cataract Extraction | 4 | 2019 | 481 | 0.780 |
Why?
|
Ophthalmology | 3 | 2018 | 508 | 0.580 |
Why?
|
Candidemia | 1 | 2012 | 29 | 0.420 |
Why?
|
Intraoperative Complications | 1 | 2018 | 1198 | 0.390 |
Why?
|
Eye Diseases | 1 | 2012 | 669 | 0.280 |
Why?
|
Refraction, Ocular | 2 | 2019 | 182 | 0.270 |
Why?
|
Clinical Competence | 2 | 2018 | 4687 | 0.260 |
Why?
|
Curriculum | 1 | 2018 | 3605 | 0.260 |
Why?
|
Phacoemulsification | 2 | 2019 | 149 | 0.250 |
Why?
|
Lenses, Intraocular | 2 | 2019 | 140 | 0.180 |
Why?
|
Hyperopia | 1 | 2019 | 44 | 0.180 |
Why?
|
Internship and Residency | 3 | 2018 | 5788 | 0.170 |
Why?
|
Pseudophakia | 1 | 2013 | 62 | 0.120 |
Why?
|
Exfoliation Syndrome | 1 | 2014 | 110 | 0.120 |
Why?
|
Solitary Fibrous Tumor, Pleural | 1 | 2013 | 25 | 0.110 |
Why?
|
Postoperative Care | 1 | 2019 | 1486 | 0.110 |
Why?
|
Lens Implantation, Intraocular | 1 | 2013 | 192 | 0.100 |
Why?
|
Candida | 1 | 2012 | 172 | 0.100 |
Why?
|
Orbital Neoplasms | 1 | 2013 | 225 | 0.090 |
Why?
|
Ultraviolet Rays | 1 | 2014 | 1060 | 0.090 |
Why?
|
Catheter-Related Infections | 1 | 2012 | 252 | 0.080 |
Why?
|
Visual Acuity | 2 | 2016 | 2530 | 0.080 |
Why?
|
Massachusetts | 2 | 2018 | 8663 | 0.080 |
Why?
|
Pleural Neoplasms | 1 | 2013 | 607 | 0.080 |
Why?
|
Caffeine | 1 | 2012 | 699 | 0.080 |
Why?
|
Coffee | 1 | 2012 | 578 | 0.080 |
Why?
|
Antifungal Agents | 1 | 2012 | 730 | 0.070 |
Why?
|
Intraocular Pressure | 1 | 2012 | 1270 | 0.070 |
Why?
|
Abdomen | 1 | 2012 | 1118 | 0.070 |
Why?
|
Glaucoma, Open-Angle | 1 | 2012 | 706 | 0.070 |
Why?
|
Teaching | 1 | 2013 | 1174 | 0.070 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 2291 | 0.060 |
Why?
|
Central Nervous System Stimulants | 1 | 2012 | 1148 | 0.060 |
Why?
|
General Surgery | 1 | 2013 | 1636 | 0.050 |
Why?
|
Heart Rate | 1 | 2012 | 4091 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2014 | 4234 | 0.050 |
Why?
|
Incidence | 1 | 2018 | 20947 | 0.040 |
Why?
|
Boston | 1 | 2012 | 9313 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2019 | 77449 | 0.040 |
Why?
|
Benchmarking | 2 | 2016 | 1042 | 0.040 |
Why?
|
Postoperative Complications | 3 | 2019 | 15295 | 0.040 |
Why?
|
Blood Pressure | 1 | 2012 | 8554 | 0.040 |
Why?
|
Kidney Neoplasms | 1 | 2013 | 4262 | 0.030 |
Why?
|
Prevalence | 1 | 2012 | 15226 | 0.030 |
Why?
|
Middle Aged | 7 | 2019 | 213383 | 0.030 |
Why?
|
Leisure Activities | 1 | 2014 | 311 | 0.030 |
Why?
|
Sunlight | 1 | 2014 | 325 | 0.030 |
Why?
|
Occupations | 1 | 2014 | 517 | 0.030 |
Why?
|
Gonioscopy | 1 | 2012 | 157 | 0.030 |
Why?
|
Israel | 1 | 2014 | 796 | 0.030 |
Why?
|
Tonometry, Ocular | 1 | 2012 | 237 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2013 | 657 | 0.020 |
Why?
|
Humans | 10 | 2019 | 744343 | 0.020 |
Why?
|
Ocular Hypertension | 1 | 2012 | 198 | 0.020 |
Why?
|
Ophthalmologic Surgical Procedures | 1 | 2013 | 349 | 0.020 |
Why?
|
Male | 7 | 2019 | 350118 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2013 | 63114 | 0.020 |
Why?
|
Risk Factors | 2 | 2014 | 72290 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 2013 | 1179 | 0.020 |
Why?
|
Postoperative Period | 1 | 2013 | 1842 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2013 | 1850 | 0.020 |
Why?
|
Aged | 5 | 2019 | 163280 | 0.020 |
Why?
|
Female | 6 | 2019 | 380194 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2012 | 2029 | 0.020 |
Why?
|
Beverages | 1 | 2012 | 820 | 0.020 |
Why?
|
Adult | 4 | 2013 | 214055 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2019 | 57776 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1434 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2014 | 2050 | 0.020 |
Why?
|
Adolescent | 1 | 2012 | 85781 | 0.010 |
Why?
|
Neoplasms | 1 | 2012 | 21683 | 0.010 |
Why?
|
Prospective Studies | 2 | 2019 | 53288 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 8642 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2012 | 12026 | 0.010 |
Why?
|
Risk Assessment | 1 | 2019 | 23338 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2014 | 21746 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 13695 | 0.010 |
Why?
|
United States | 1 | 2014 | 69872 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2013 | 35421 | 0.000 |
Why?
|